Harpoon Therapeutics, Inc
4000 Shoreline Court, Suite 250
South San Francisco
CA
94080
United States
144 articles about Harpoon Therapeutics, Inc
-
Harpoon Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update
5/6/2020
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company developing a novel class of T cell engagers, reported financial results for the first quarter ended March 31, 2020 and provided a corporate update.
-
Clinical Catch-Up: April 27-May 1
5/4/2020
There’s plenty of news related to clinical trials related to COVID-19, but it does seem to be drowning out non-COVID-19-related clinical trials. Here’s a look. -
Harpoon Therapeutics Doses First Patient with HPN217, a BCMA Targeting TriTAC, for Multiple MyelomaInitiation of the clinical trial triggers $50 million milestone payment from AbbVie
4/27/2020
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company developing a novel class of T cell engagers, announced that the first patient has been dosed with HPN217 in a Phase 1/2 clinical trial focused on relapsed, refractory multiple myeloma.
-
Harpoon Therapeutics Appoints Two New Members to Its Board of Directors
4/1/2020
Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that it has appointed Andrew R. Robbins and Joseph S. Bailes, M.D., to its Board of Directors. Among his many achievements, Mr. Robbins is credited with leading the highly successful U.S. launch of BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) in BRAF-mutant metastatic melanoma
-
Harpoon Therapeutics Reports Fourth Quarter 2019 Financial Results and Provides Corporate Update
3/12/2020
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company developing a novel class of T cell engagers, reported financial results for the fourth quarter and full year ended December 31, 2019 and provided a corporate update.
-
Harpoon Therapeutics to Report Fourth Quarter 2019 Financial Results and Provide Corporate Update
3/5/2020
Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, announced today that it will report fourth quarter and full year 2019 financial results and provide a corporate update on Thursday, March 12, 2020
-
Harpoon Therapeutics to Participate in Two Upcoming Investor Conferences
2/20/2020
Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that Gerald McMahon, Ph.D., President and Chief Executive Officer, will participate in two upcoming investor conferences
-
Harpoon Therapeutics to Participate in the Piper Jaffray Healthcare Conference
11/26/2019
Harpoon Therapeutics, Inc. announced that Gerald McMahon, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the 31st Annual Piper Jaffray Healthcare Conference.
-
Harpoon Therapeutics and AbbVie Announce Licensing and Option Collaboration to Advance HPN217, Harpoon’s BCMA-Targeting TriTAC®, and Expand Existing Discovery Collaboration
11/21/2019
Harpoon grants AbbVie option to license worldwide rights to HPN217 (BCMA), a TriTAC for the treatment of multiple myeloma planned for IND filing this year
-
The new deal builds on a discovery agreement signed in October 2017.
-
Harpoon Therapeutics to Participate in Two Upcoming Investor Conferences
11/12/2019
Harpoon Therapeutics, Inc. announced that Gerald McMahon, Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences
-
Harpoon Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate Update
11/6/2019
Continued enrollment and dose escalation of Phase 1 trial for HPN424 and Phase 1/2a trial for HPN536, Harpoon’s lead TriTAC® product candidates in development for the treatment of prostate and ovarian and pancreatic cancers, respectively.
-
Harpoon Therapeutics Presents Preclinical Data for HPN328, a DLL3-targeting T Cell Engager, at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
10/29/2019
Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today presented a poster showing preclinical data supporting HPN328 as a treatment for small cell lung cancer (SCLC) at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics meeting in Boston.
-
Harpoon Therapeutics Announces Presentation on HPN328 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
10/22/2019
Harpoon Therapeutics, Inc. announced that an abstract regarding HPN328 for the treatment of small cell lung cancer has been accepted for poster presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.
-
Harpoon Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
3/14/2019
Lead Tri-specific T cell Activating Construct (TriTAC) candidate, HPN424, continues to advance in a Phase 1 clinical trial for the treatment of prostate cancer
-
A summary of IPOs from companies in the biotech and pharma world since February 1, 2019.
-
Harpoon Therapeutics Announces Pricing of Initial Public Offering on February 8, 2019
2/8/2019
Harpoon Therapeutics, Inc. announced the pricing of its initial public offering of 5,400,000 shares of its common stock at a price to the public of $14.00 per share.
-
The government shutdown threw a wrench into several biotech company’s plans for initial public offerings (IPOs). Although the government is only guaranteed to stay open until February 15, several biotechs are working to get their IPOs launched in that window. Here’s a look.
-
Harpoon Therapeutics Announces Preliminary Safety and Pharmacology Data from its HPN424 Phase 1 Trial in Prostate Cancer
1/2/2019
Initial data shows HPN424 serum exposure supports weekly dosing Changes in blood-derived tumor cell and serum biomarkers consistent with T cell activation HPN424 dose escalation proceeding to identify Phase 2 therapeutic dose
-
A summary of IPOs from companies in the biotech and pharma world since December 1, 2018.